Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer

(2020) L.R. Duska et al.   GYNECOLOGIC ONCOLOGY

Epithelial ovarian cancer

(2019) Stephanie Lheureux et al.   LANCET

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper

(2017) Thomas J. Herzog et al.   GYNECOLOGIC ONCOLOGY

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

(2016) S. M. Keefe et al.   ANNALS OF ONCOLOGY

CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing

(2016) Andrew J. Clark et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial

(2015) Andres M. Poveda et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Camptothecin Resistance in Cancer: Insights into the Molecular Mechanisms of a DNA-Damaging Drug

(2013) G. L. Beretta et al.   CURRENT MEDICINAL CHEMISTRY

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

(2013) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS